How to manage the risk of colorectal cancer in ulcerative colitis

Raja Affendi Raja Ali, Laurence John Egan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are 'at-risk' of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.

Original languageEnglish
Pages (from-to)1424-1432
Number of pages9
JournalCurrent Drug Targets
Volume12
Issue number10
DOIs
Publication statusPublished - Sep 2011
Externally publishedYes

Fingerprint

Ulcerative Colitis
Inflammatory Bowel Diseases
Colorectal Neoplasms
Early Detection of Cancer
Mucous Membrane
Surgery
Inflammation
Morbidity
Mortality
Neoplasms

Keywords

  • Colectomy
  • Colorectal cancer
  • Dysplasia
  • Inflammatory bowel disease
  • Surveillance colonoscopy
  • Ulcerative colitis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

How to manage the risk of colorectal cancer in ulcerative colitis. / Raja Ali, Raja Affendi; Egan, Laurence John.

In: Current Drug Targets, Vol. 12, No. 10, 09.2011, p. 1424-1432.

Research output: Contribution to journalArticle

Raja Ali, Raja Affendi ; Egan, Laurence John. / How to manage the risk of colorectal cancer in ulcerative colitis. In: Current Drug Targets. 2011 ; Vol. 12, No. 10. pp. 1424-1432.
@article{936b955c987445e79b1e0f226ecf391b,
title = "How to manage the risk of colorectal cancer in ulcerative colitis",
abstract = "There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are 'at-risk' of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.",
keywords = "Colectomy, Colorectal cancer, Dysplasia, Inflammatory bowel disease, Surveillance colonoscopy, Ulcerative colitis",
author = "{Raja Ali}, {Raja Affendi} and Egan, {Laurence John}",
year = "2011",
month = "9",
doi = "10.2174/138945011796818270",
language = "English",
volume = "12",
pages = "1424--1432",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - How to manage the risk of colorectal cancer in ulcerative colitis

AU - Raja Ali, Raja Affendi

AU - Egan, Laurence John

PY - 2011/9

Y1 - 2011/9

N2 - There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are 'at-risk' of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.

AB - There is a strong association between chronic inflammation and cancer formation. This correlation has been well observed in patients with long standing inflammatory bowel disease (IBD) who are at high risk of colorectal cancer (CRC). At present, there is a lack of good markers for predicting the progression from normal to neoplastic mucosa in patients with IBD. IBD patients who are 'at-risk' of CRC should be identified, evaluated and should also be enrolled in surveillance program, regardless of their disease activity. Early identification of dysplasia and its appropriate management using endoscopic techniques or surgery are essential in patients with long-standing IBD, to minimize CRC morbidity and mortality. Gastroenterologists should work along with experienced, specialised gastrointestinal pathologists, surgeons and with fully informed and compliant IBD patients' to ensure the success of surveillance programme in early detection of CRC.

KW - Colectomy

KW - Colorectal cancer

KW - Dysplasia

KW - Inflammatory bowel disease

KW - Surveillance colonoscopy

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=80051674817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051674817&partnerID=8YFLogxK

U2 - 10.2174/138945011796818270

DO - 10.2174/138945011796818270

M3 - Article

C2 - 21466491

AN - SCOPUS:80051674817

VL - 12

SP - 1424

EP - 1432

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 10

ER -